INDIGO STAR (08373) announced its mid-year performance for 2025. The company's attributable net profit decreased by 6.23% to 2.169 million Singapore dollars.
Indigo Blue Star (08373) announced its mid-year performance in 2025, with revenue of 38.048 million patacas, a decrease of 1.64% year-on-year; the company's owners' share of net profit for the period amounted to 2.169 million patacas, a decrease of 6.23% year-on-year; earnings per share were 5.35 patacas.
Indigo Star (08373) announced its performance for the mid-year of 2025, with a revenue of 38,048,000 Singapore dollars, a decrease of 1.64% year-on-year; the net profit attributable to owners of the company was 2,169,000 Singapore dollars, a decrease of 6.23% year-on-year; earnings per share were 5.35 Singapore cents.
Related Articles
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)
From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?
New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)
From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?
New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
RECOMMEND
Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026
Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026
2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026
